key: cord-0843621-nnwiteg5
authors: Snowden, Caroline; Ng, Spencer; Choi, Jaehyuk
title: Partial Remission of Advanced Untreated Sezary Syndrome after COVID-19
date: 2022-01-06
journal: JAAD Case Rep
DOI: 10.1016/j.jdcr.2021.12.005
sha: 42d9804e777d4577a56022047499bb03d482ca6b
doc_id: 843621
cord_uid: nnwiteg5

nan

Here we report the case of a woman with untreated SS who experienced a partial 35 remission of her disease after two COVID-19 courses before eventually succumbing to a third 36 SARS-CoV-2 infection. 37 38

Case Report 39 40

In the fall of 2019, a 66-year-old female presented with a sudden onset of diffuse pruritus 41 and erythroderma. Biopsy revealed atypical cells with irregular nuclei in the dermis and epidermis 42 (Figure 1) . Flow cytometry showed an abnormal CD3+CD4+CD7-CD26-T-cell clone. 43

Hematopathology showed a Sezary cell count of 2312. A PET scan showed bilateral 44 lymphadenopathy in the neck, axilla, and inguinal region (Figure 2) . The patient received a 45 diagnosis of stage IVA1 (T4NxM0B2) Sezary Syndrome. Her medical history was significant for 46 uncontrolled hypertension, type 2 diabetes and end-stage renal disease. 47

She was prescribed extracorporeal photopheresis and bexarotene but was lost to follow-48 up. Untreated, her pruritus worsened to a level precluding sleep and her Sezary count climbed to 49 11132 (Figure 3) (Table 1) .

In April 2020, the patient was infected with SARS-CoV-2. She was short of breath but 51 afebrile. Because of her mild clinical course, she recovered fully without medication. Two months 52 later, her Sezary count dropped to 6494, a 42% drop from March (Figure 3 ). 53

In July 2020, the patient was admitted to the hospital with severe COVID-19. She 54 experienced shortness of breath, chills, fever (38.5 C), and hypoxemia (70% O2 saturation on 55 room air). She had a protracted 25-day stay with multiple admissions to the intensive care unit 56 (ICU). During this hospital course, she received 6 mg dexamethasone for the first 8 days and 57 empiric antibiotics for 25 days for what was later determined to be a false positive blood culture. 58

She did not receive SS treatment, but her lymphocyte count began to decrease on hospital day 59 14. At discharge, her absolute lymphocyte count (which includes Sezary cells) was the lowest 60 ever recorded (1900, 87% decrease from peak) (Figure 3) . 61

The patient returned to clinic in September 2020 whereupon her Sezary count had 62 dropped to 936 (92% decrease from peak). She began a course of romidepsin, a histone 63 deacetylase inhibitor and FDA-approved therapy for cutaneous T cell lymphoma. In October 2020, 64

her pruritus was improved and her erythroderma and lymphadenopathy resolved. Her Sezary 65 counts dropped to 389 (97% decrease from peak). 66

In November, the patient was admitted to the ICU again for severe Interestingly, our patient had remarkable improvements in her tumor burden after each 78 SARS-CoV-2 infection (Figure 3) Alternatively, her drop in tumor burden may be due to heterologous immunity. 97

Heterologous immunity is the induction of T-cell response to one pathogen after priming by 98

another J o u r n a l P r e -p r o o f

European Organisation for Research and Treatment of Cancer 135 consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome -136 Update

Integrated Genomic Analyses of Cutaneous T Cell Lymphomas Reveal the 143

Molecular Bases for Disease Heterogeneity. 2021: Blood

Immunopathogenesis and therapy of cutaneous T cell lymphoma

COVID-19 in Immunocompromised Hosts: What We Know So 147

COVID-19 infection in patients with Sezary syndrome: Report of two 149 cases

Genomic evidence for reinfection with SARS-CoV-2: a case study

Prolonged Severe Acute Respiratory Syndrome Coronavirus

Replication in an Immunocompromised Patient

The before and after a COVID-19 pneumonia CT scan. ‼Complete 157 response of relapsed stage IV lung squamous carcinoma (bilateral lung and liver mets)

What the mystery is behind? #LCSM #coronavirus #COVIDー19

SARS-CoV-2-induced remission of Hodgkin lymphoma

Untuned antiviral immunity in COVID-19 revealed by temporal type 163

Primary Cutaneous Lymphomas. 2019. 165 13

Progression of undiagnosed cutaneous lymphoma after anti-167 tumor necrosis factor-alpha therapy

Fueling Cancer Immunotherapy With Common Gamma Chain 169

Interferon Lambda: Toward a Dual Role in Cancer

Incidence of spontaneous remission in patients with CD25-positive 173 mycosis fungoides/Sezary syndrome receiving placebo

Immunity to commensal papillomaviruses protects against skin 176 cancer

Cross-reactive memory T cells and herd immunity to SARS-CoV-2

Presence of antibody-dependent cellular cytotoxicity (ADCC) against

SARS-CoV-2 in COVID-19 plasma

Diverse Functional Autoantibodies in Patients with COVID-19